TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25202937
Drug: Segmental epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental epidural steroid injection (80 mg of triamcinolone)
Study: 22227611
Drug: Told alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Told alcohol (0.4 g/kg ethanol)
Study: 22227611
Drug: Told placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Told placebo (0.0 g/kg ethanol)
Study: 12534378
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 50 mg
Study: 1574244
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (1,500-2,500 mg/m2)
Study: 1574244
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (2,000 mg/m2 or greater)
Study: 1574244
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (1,500 mg/m2)
Study: 2864849
Drug: Esmolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (mean dosage 142 +/- 100 micrograms/kg/min, range 50 to 300 micrograms/kg/min)
Study: 2864849
Drug: Nitroprusside (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside (mean dose 1.6 +/- 1.3 micrograms/kg/min, range 0.5 to 2.75 micrograms/kg/min)
Study: 29462224
Drug: Tavaborole 5%
Normalized name: TAVABOROLE 5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tavaborole 5% topical treatment
Study: 27108476
Drug: Immediate non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate non-surgical periodontal therapy
Study: 27108476
Drug: Delayed non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed non-surgical periodontal therapy (Control)
Study: 24675394
Drug: Standard AI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AI treatment plus educational materials (EMs)
Study: 24675394
Drug: Standard AI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AI treatment
Study: 18456568
Drug: rifaximin therapy
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin therapy (1200 mg/day for 10 days)
Study: 18456568
Drug: rifaximin therapy
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin therapy (after placebo)
Study: 18456568
Drug: rifaximin therapy
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin therapy (for patients with negative BTs)
Study: 16181529
Drug: CHD Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHD Capsules (CHDC)
Study: 16181529
Drug: Compound Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Prescription Danshen Droplet Pills (CPDDP)
Study: 10381807
Drug: Codeine 120
Normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 120 mg with placebo
Study: 10381807
Drug: Codeine 120
Normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 120 mg with quinidine 100 mg
Study: 8682138
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg bd
Study: 8682138
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg bd
Study: 1986659
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) - 20-25 micrograms/kg
Study: 1986659
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of meperidine (1.5 mg/kg), diazepam (0.2 mg/kg), and atropine (0.02 mg/kg)
Study: 1986659
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of meperidine, diazepam, and atropine
Study: 28902580
Drug: PFO closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFO closure plus antiplatelet therapy
Study: 27266281
Drug: Nebulised magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised magnesium sulphate (MS) 151 mg/dose with ipratropium bromide (IB) 500 µg
Study: 27266281
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with ipratropium bromide (IB) 500 µg
Study: 7943519
Drug: Ligament augmentation
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligament augmentation device
Study: 12435652
Drug: No ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ligament augmentation device (control)
Study: 1940965
Drug: CDP‐choline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP‐choline (1 g)
Study: 7038950
Drug: Doxapram hydrochloride
Normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxapram hydrochloride infusions
Study: 31048443
Drug: Intranasal inoculation
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal inoculation of genetically modified N. lactamica expressing the meningococcal antigen NadA
Study: 30049309
Drug: Etripamil nasal
Normalized name: etripamil
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil nasal spray (various doses)
Study: 30049309
Drug: Etripamil nasal
Normalized name: etripamil
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil nasal spray (highest dose)
Study: 22104564
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy for 53 weeks
Study: 22104564
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy
Study: 19156973
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg(‐1) rocuronium
Study: 6385607
Drug: Mucosolvan (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvan (60 mg X 2 daily)
Study: 28508561
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 4 h before IVI and topical diclofenac 45 min before IVI
Study: 28508561
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 45 min before IVI
Study: 28508561
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (oral and topical diclofenac)
Study: 25382404
Drug: Pleurotus ostreatus
Normalized name: Pleurotus ostreatus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleurotus ostreatus (P.o) and Pleurotus cystidiosus (P.c) at a dose of 50 mg/kg/body weight
Study: 21849415
Drug: Nicotine mouth
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mouth spray 4 mg
Study: 21849415
Drug: Nicotine mouth
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mouth spray 2 mg
Study: 21849415
Drug: Nicotine mouth
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mouth spray 1 mg
Study: 21849415
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge 4 mg
Study: 21849415
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum 4 mg
Study: 16332282
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus self-help
Study: 8057661
Drug: Intensified protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified protocol with high-dose chemotherapy and autologous or allogeneic bone marrow transplantation
Study: 8057661
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment from previous trials
Study: 2923766
Drug: Plain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain 0.5% bupivacaine 3 ml
Study: 2923766
Drug: Plain 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain 0.25% bupivacaine 6 ml
Study: 29984832
Drug: Novel chocolate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel chocolate-based tablet formulation of midazolam (0.5 mg.kg−1)
Study: 29984832
Drug: Intravenous solution
Normalized name: Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution of midazolam (0.5 mg.kg−1)
Study: 29984832
Drug: Novel chocolate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel chocolate-based tablet formulation of midazolam
Study: 19255206
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (28 knees)
Study: 19255206
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (36 knees)
Study: 12970272
Drug: 30 mCi
Normalized name: Xofigo 30 MCI/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mCi (131)I with rhTSH stimulation after stopping L-T4
Study: 12970272
Drug: 30 mCi
Normalized name: Xofigo 30 MCI/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mCi (131)I in hypothyroid state after L-T4 withdrawal
Study: 12970272
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving rhTSH without stopping L-T4
Study: 9258101
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative subcutaneous heparin
Study: 2438924
Drug: Pirmenol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol hydrochloride 300 mg/day
Study: 2438924
Drug: Pirmenol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol hydrochloride 400 mg/day
Study: 22399700
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise (30 min of cycling exercise at 50% maximal workload capacity)
Study: 12552940
Drug: Early intensification
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensification chemotherapy
Study: 353680
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications
Study: 353680
Drug: Placebo medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medications
Study: 27910156
Drug: Ixekizumab Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q4W (80 mg every 4 weeks after a 160 mg starting dose)
Study: 27910156
Drug: Ixekizumab Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q2W (80 mg every 2 weeks after a 160 mg starting dose)
Study: 25367222
Drug: BF‐FES +
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF‐FES + mirror therapy
Study: 25367222
Drug: FES +
Normalized name: Ferric Ethylenediamine Tetraacetic Acid (Ferric EDTA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES + mirror therapy
Study: 25367222
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional physical therapy program)
Study: 23794414
Drug: Tolvaptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (5 to 240 mg)
Study: 12927001
Drug: Venlafaxine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (up to 150 mg/day)
Study: 7645699
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen administration (up to 6 l.min‐1)
Study: 2144019
Drug: Ondansetron 5
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 5 mg/m2 IV (group A)
Study: 2144019
Drug: Ondansetron 3
Normalized name: ondansetron 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 3 mg/m2 IV (group B)
Study: 7009593
Drug: Alprazolam (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2.2 mg daily for 21 days)
Study: 7009593
Drug: Diazepam (20.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (20.2 mg daily for 21 days)
Study: 31387097
Drug: Molidustat in
Normalized name: Molidustat
DrugBank: Molidustat (DB15642)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molidustat in treatment-naïve patients not on dialysis
Study: 28470100
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 µg/kg (D1)
Study: 28470100
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg (D2)
Study: 28470100
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg/kg (D3)
Study: 21849729
Drug: DD current
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DD current therapy
Study: 16278260
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) plus testosterone (T) implants
Study: 16278260
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) implants alone
Study: 12921985
Drug: Homocysteine concentration
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homocysteine concentration >12 micromol/l
Study: 12921985
Drug: Erythrocyte S-adenosylmethionine
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocyte S-adenosylmethionine concentration >4000 nmol/l
Study: 8677737
Drug: G‐CSF/IL‐3 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF/IL‐3 combination
Study: 20214527
Drug: Lapatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib monotherapy
Study: 12488257
Drug: New topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topical cysteamine formulation
Study: 12488257
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of topical cysteamine
Study: 11817492
Drug: Opioid taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid taper algorithm (phase 2)
Study: 7258124
Drug: Commercial multivitamin‐multimineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial multivitamin‐multimineral supplement
Study: 24768161
Drug: Prenatal drug
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal drug exposure (PDE)
Study: 24768161
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and perceived peer drug use
Study: 23975326
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g oil (rapeseed) with 3 μm droplet size
Study: 23975326
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g oil (rapeseed) with 0.1 μm droplet size
Study: 23975326
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g oil (rapeseed) with 3 μm droplet size
Study: 23975326
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g oil (rapeseed) with 0.1 μm droplet size
Study: 16040729
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) solution applied every 6 months for 36 months
Study: 16040729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SDF treatment)
Study: 8470424
Drug: NIB-14 vaccine
Normalized name: pneumococcal capsular polysaccharide type 14 vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide antigen (DB10332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIB-14 vaccine
Study: 8470424
Drug: NIB-17 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIB-17 vaccine
Study: 8470424
Drug: Cross-reactive antibodies
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-reactive antibodies
Study: 2879960
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily) during intravenous clorazepate administration
Study: 23500276
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial appendage closure device (warfarin naive subgroup)
Study: 23500276
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (warfarin naive subgroup)
Study: 22076546
Drug: Daclizumab monotherapy
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab monotherapy for 54 weeks
Study: 16772027
Drug: PD on
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD on medication
Study: 16772027
Drug: PD off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD off medication
Study: 11808969
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once weekly)
Study: 11808969
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg q.i.d. for last week)
Study: 28610605
Drug: Treatment completion
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment completion
Study: 7569760
Drug: Oral cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cromolyn sodium (1500 mg/day) for 1 month
Study: 27206923
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including denture placement immediately after extractions
Study: 23107353
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion site warming device (InsuPatch)
Study: 12837861
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n = 12); daily extension and flexion range of motion against passive resistance (5 minutes per day, 5 days per week, for 4 weeks)
Study: 8794955
Drug: Inhaled methanol
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methanol at 200 ppm for 4 hours
Study: 2004725
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg intravitreal dexamethasone phosphate
Study: 6346848
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg
Study: 6346848
Drug: Indapamide, 2.5
Normalized name: Indapamide, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide, 2.5 mg
Study: 20737518
Drug: Multi-vitamin/mineral supplement
Normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-vitamin/mineral supplement (Supradyn)
Study: 12947070
Drug: Clodronate 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,500 mg IV every 3 weeks + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Study: 12947070
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Study: 10493337
Drug: Conventional inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inactivated influenza A vaccine
Study: 8614525
Drug: 311C90 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311C90 1 mg
Study: 8614525
Drug: 311C90 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311C90 5 mg
Study: 8614525
Drug: 311C90 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311C90 25 mg
Study: 1533289
Drug: Intravenous m-chlorophenylpiperazine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous m-chlorophenylpiperazine (MCPP) 0.06 mg/kg
Study: 1533289
Drug: Intravenous m-chlorophenylpiperazine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous m-chlorophenylpiperazine (MCPP) 0.08 mg/kg
Study: 3919556
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of bepridil hydrochloride
Study: 3919556
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of bepridil hydrochloride
Study: 3919556
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of bepridil hydrochloride
Study: 22743160
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT)
Study: 20693799
Drug: Intravenous sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sotalol (75 mg over 2.5 h)
Study: 20693799
Drug: Oral sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sotalol (80 mg)
Study: 16151353
Drug: Prednisone (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.35 mg/kg daily for 18 weeks)
Study: 16151353
Drug: Diphenidol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h)
Study: 10695780
Drug: Dihydroartemisinin 480
Normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dihydroartemisinin 480 mg over 5 days
Study: 10695780
Drug: Dihydroartemisinin 640
Normalized name: Succinyl dihydroartemisinin
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dihydroartemisinin 640 mg over 7 days
Study: 7827868
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (MAb) and complement treatment
Study: 3163879
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Zn/d
Study: 3163879
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Zn/d
Study: 23180503
Drug: Protocolized sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized sedation plus daily sedation interruption (n = 214)